They'll still need to do a P3, from what I've read about accelerated approvals and still needing to go through the whole clinical trials pathway. For what it's worth, I believe a raise will/should happen irrespective of accelerated approval. I believe, as a company, you don't want to be looking down the barrel of a buyout with little funds., it doesn't allow you to negotiate from a position of strength.
whether for financial leverage or needing funds for a P3, I feel a raise will happen, but not for a long time and hopefully at a significantly higher SP.
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?, page-172
-
- There are more pages in this discussion • 220 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.54 |
Change
-0.015(0.97%) |
Mkt cap ! $261.5M | |||
| Open | High | Low | Value | Volume |
| $1.55 | $1.55 | $1.50 | $111.4K | 73.35K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $1.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.56 | 1400 | 1 |
View Market Depth
| Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |